FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced the results from the first hemiablation procedures for prostate cancer treatments in a United Kingdom-based study using the Sonablate 500 (“SB500”), a medical device using high intensity focused ultrasound (“HIFU”) that is manufactured and distributed in Europe by Misonix. According to Dr. Mark Emberton, a leading surgeon for the study and member of the Clinical Effectiveness Unit of the Royal College of Surgeons of England, London, UK, the results show that the hemiablation procedures were successfully completed with positive ablation of cancerous tissue in the effected area of the prostate gland, and patients showed 100% continence and 100% potency in follow-up examinations. Unlike many of the traditional prostate cancer surgeries which treat or remove the entire gland, HIFU hemiablation using the SB500 involves ablation of cancer in patients who have had biopsy-proven prostate cancer limited to one side of the prostate.
